Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NOX4 | Q9NPH5 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348778 | 0.84 | DRD2 (0.53) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL4711615 | 0.84 | MAPT (0.44) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL6362778 | 0.81 | MEN1 (0.61) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL20057689 | 0.79 | DRD2 (0.36) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL25685276 | 0.79 | MGLL (0.43) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL20313983 | 0.79 | GAA (0.49) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL21594891 | 0.78 | CHKA (0.50) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL21594874 | 0.78 | RAB9A (0.42) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL2555563 | 0.78 | HRH3 (0.37) | MEN1NPC1RAB9AKMT2ADRD2 | |
| SCHEMBL4709988 | 0.77 | LMNA (0.54) | HRH3ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | MEN1 1386/4885NPC1 2455/4885RAB9A 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.